

February 18, 2025



Sigyn Therapeutics to Present at Tomorrow's Emerging Growth Conference

The Company invites investors, industry executives, and analysts to attend its real-time, interactive presentation

SAN DIEGO, February 18, 2025 -- Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB: SIGY), a developer of next-generation blood purification therapies to address cancer and life-threatening infectious disease disorders, today announced that Jim Joyce, the Company's CEO will give a live presentation at tomorrow's Emerging Growth Conference.

Date: February 19th

Time: 4:10pm – 4:40pm Eastern

Registration: https://goto.webcasts.com/starthere.jsp?ei=1696664&tp_key=a17d7ff4c2&sti=sigy

This will be a live, interactive online event where participants are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, <http://www.YouTube.com/EmergingGrowthConference>.

About Sigyn Therapeutics™

Sigyn Therapeutics is developing next-generation blood purification therapies to address cancer and life-threatening infectious disease disorders that are not treatable with drugs. The Company's lead product candidate, Sigyn Therapy™ has been demonstrated to reduce the presence of viral pathogens, bacterial toxins, and pro-inflammatory cytokines from human blood plasma. Based on these capabilities, Sigyn Therapy™ is a candidate to treat life-threatening viral pathogens, antibiotic-resistant bacterial infections, endotoxemia, and sepsis, which is the leading cause of death in U.S. hospitals. The clinical protocol of first-in-human studies incorporates Sigyn Therapy with regularly scheduled dialysis treatments to address endotoxemia and concurrent inflammation, which are highly prevalent disorders that shorten the lives of end-stage renal disease (ESRD) patients. Extending the lives of those with ESRD could significantly impact dialysis industry revenues.

The Company's oncology pipeline is comprised of ImmunePrep™, a platform to enhance the delivery of immunotherapeutic antibodies; ChemoPrep™ to improve the delivery of chemotherapeutic agents; and ChemoPure™ to reduce chemotherapy toxicity. If successfully advanced, the Company's therapies offer to provide strategic value to the dialysis and biopharmaceutical industry.

To learn more about Sigyn Therapeutics, visit: www.SigynTherapeutics.com

About the Emerging Growth Conference

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

CONTACTS:

Sigyn Therapeutics, Inc.

Johan Louw
Senior Vice President of Strategic Programs
281.660.1815
jlouw@SigynTherapeutics.com

Jim Joyce
CEO, Inventor
Email: jj@SigynTherapeutics.com

Cautionary Note Regarding Forward-Looking Statements

This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. ("Sigyn") that involve substantial risks and uncertainties. All statements contained in this summary are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Sigyn's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences may include, without limitation, the Company's ability to clinically advance Sigyn Therapy in human studies required for market clearance, the Company's ability to manufacture Sigyn Therapy, the Company's ability to raise capital resources, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this report speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it

undertake any duty, to update this information to reflect future events or circumstances.